Skip to content

Effects of rTMS on Human Brain Activity Measured With fMRI

Effects of rTMS on Human Brain Activity Measured With fMRI

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03259568
Enrollment
27
Registered
2017-08-23
Start date
2018-01-12
Completion date
2019-08-20
Last updated
2023-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Brain Activity

Keywords

TMS, BOLD activity, Network activity

Brief summary

This project investigates the effects of repetitive transcranial magnetic stimulation (rTMS) on neural circuits as a function of spatiotemporal parameters and brain state in order to better understand why the method works and how to improve its efficacy. Leveraging our expertise in application of TMS methodology during concurrent single neuron recording techniques in non-human primates and imaging and scalp potential techniques in humans, the investigators aim to resolve three interlocking problems in the design and application of rTMS: stimulation frequency, spatial targeting, and interactions with brain state.

Interventions

1-10 Hertz rTMS will be administered

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Masking description

Participant is not informed about TMS intensity.

Intervention model description

The study is a within-subjects design focused on estimating the fMRI BOLD response to different levels of TMS intensity. The conditions in the study (arms) are repeated within each participant (20%, 40%, 80%, or 120% of an individual's titrated resting motor threshold).

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age between 18-30. 2. Use of effective method of birth control for women of childbearing capacity. 3. Willing to provide informed consent.

Exclusion criteria

1. Current or recent (within the past 6 months) of substance abuse or dependence, excluding nicotine and caffeine (urine test). 2. Current serious medical illness (self report). 3. History of seizure except those therapeutically induced by ECT (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, cranial metal implants, known structural brain lesion, devices that may be affected by rTMS or MRI (pacemaker, medication pump, cochlear implant, implanted brain stimulator); \[TMS Adult Safety Screening (TASS) form\]. 4. Subjects are unable or unwilling to give informed consent. 5. Diagnosed any Axis I DSM-IV disorder (MINI, DSM-IV) 6. Subjects with a clinically defined neurological disorder including, but not limited to: 1. Any condition likely to be associated with increased intracranial pressure 2. Space occupying brain lesion. 3. History of stroke. 4. Transient ischemic attack within two years. 5. Cerebral aneurysm. 6. Dementia. 7. Mini Mental Status Exam (MMSE) score of \<24. 8. Parkinson's disease. 9. Huntington's disease. i. Multiple sclerosis. 7. Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or currently taking medication that lowers the seizure threshold. 8. Subjects with cochlear implants 9. Subjects not willing to tolerate the confinement associated with being in the MRI scanner. 10. Women who are pregnant or breast-feeding (urine test). 11. Blindness. 12. Inability to read or understand English.

Design outcomes

Primary

MeasureTime frameDescription
Motion Perception Accuracyduring each TMS session, up to 3 hoursAcute effect of a rTMS session on the performance for a motion task, as measured by accuracy (in percentage of correct responses)
Reaction Timeduring each TMS session, up to 3 hoursAcute effect of a rTMS session on the performance for a motion task, as measured by reaction time (in ms)
Activation of Cortical Networks During a Visual Motion Task.during each TMS session, up to 3 hoursAcute effect of a rTMS session on fMRI activation during a motion task, as measured by the change in BOLD signal

Countries

United States

Participant flow

Participants by arm

ArmCount
Active rTMS (Repetitive Transcranial Magnetic Stimulation)
Repetitive TMS: 1-10 Hertz rTMS will be administered, at varying levels of TMS intensity.
27
Total27

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyParticipant performance was low3

Baseline characteristics

CharacteristicActive rTMS (Repetitive Transcranial Magnetic Stimulation)
Age, Continuous23.7 years
STANDARD_DEVIATION 2.7
fMRI Activity
120% RMT
1.25 BOLD response
STANDARD_DEVIATION 0.15
fMRI Activity
20% RMT
1.28 BOLD response
STANDARD_DEVIATION 0.14
fMRI Activity
40% RMT
1.28 BOLD response
STANDARD_DEVIATION 0.12
fMRI Activity
80% RMT
1.20 BOLD response
STANDARD_DEVIATION 0.14
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
4 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
20 Participants
Region of Enrollment
United States
27 Participants
Sex: Female, Male
Female
16 Participants
Sex: Female, Male
Male
11 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 270 / 270 / 270 / 27
other
Total, other adverse events
0 / 270 / 270 / 270 / 27
serious
Total, serious adverse events
0 / 270 / 270 / 270 / 27

Outcome results

Primary

Activation of Cortical Networks During a Visual Motion Task.

Acute effect of a rTMS session on fMRI activation during a motion task, as measured by the change in BOLD signal

Time frame: during each TMS session, up to 3 hours

Population: Within-subjects manipulation (same subjects for each condition).

ArmMeasureValue (MEAN)Dispersion
Dose-response TMS - Intensity = 20%RMTActivation of Cortical Networks During a Visual Motion Task.0.89 BOLD activityStandard Deviation 0.06
Dose-response TMS - Intensity = 40%RMTActivation of Cortical Networks During a Visual Motion Task.0.87 BOLD activityStandard Deviation 0.05
Dose-response TMS - Intensity = 80%RMTActivation of Cortical Networks During a Visual Motion Task.0.88 BOLD activityStandard Deviation 0.06
Dose-response TMS - Intensity = 120%RMTActivation of Cortical Networks During a Visual Motion Task.0.94 BOLD activityStandard Deviation 0.04
Primary

Motion Perception Accuracy

Acute effect of a rTMS session on the performance for a motion task, as measured by accuracy (in percentage of correct responses)

Time frame: during each TMS session, up to 3 hours

Population: Within-subjects manipulation (same subjects for each condition).

ArmMeasureValue (MEAN)Dispersion
Dose-response TMS - Intensity = 20%RMTMotion Perception Accuracy63 Percentage of correct responsesStandard Error 4
Dose-response TMS - Intensity = 40%RMTMotion Perception Accuracy62 Percentage of correct responsesStandard Error 4
Dose-response TMS - Intensity = 80%RMTMotion Perception Accuracy58 Percentage of correct responsesStandard Error 4
Dose-response TMS - Intensity = 120%RMTMotion Perception Accuracy61 Percentage of correct responsesStandard Error 3
Primary

Reaction Time

Acute effect of a rTMS session on the performance for a motion task, as measured by reaction time (in ms)

Time frame: during each TMS session, up to 3 hours

Population: Within-subjects manipulation (same subjects for each condition).

ArmMeasureValue (MEAN)Dispersion
Dose-response TMS - Intensity = 20%RMTReaction Time814 millisecondsStandard Error 104
Dose-response TMS - Intensity = 40%RMTReaction Time784 millisecondsStandard Error 94
Dose-response TMS - Intensity = 80%RMTReaction Time762 millisecondsStandard Error 85
Dose-response TMS - Intensity = 120%RMTReaction Time810 millisecondsStandard Error 109

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026